Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
AssigneeThe J. David Gladstone Institutes
InventorsYadong Huang, Qin Xu, Robert W. Mahley
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for identifying candidate agents for treatment of obesity, liver disease, and/or diabetes. Such methods include, e.g., contacting a mammalian cell or cell population with a test agent, and measuring an expression level and/or activity level of ClpP in the mammalian cell or in cells of the cell population. Also provided are methods and compositions for treating an individual (e.g., one who is obese and/or has diabetes). Treatment methods include administering an inhibitor of ClpP to the individual (e.g., to prevent or reduce weight gain, to increase insulin sensitivity, and/or to increase glucose tolerance).
Claims11
A method of identifying a candidate agent for treating obesity, liver disease, and/or diabetes, the method comprising:
- (a) obtaining an expression level and/or activity level of ClpP in a sample of mammalian cells derived from a subject to obtain a reference value;
- (b) contacting a sample of cells from said subject of (a) with a test agent;
- (c) measuring an expression level and/or activity level of ClpP in the sample of cells of (b) following the contacting;
- (d) determining that the test agent caused a decrease in the expression level and/or activity level of ClpP in the sample of cells of (b) as compared to the reference value of (a);
- and
- (e) administering to said subject a composition comprising the test agent, wherein the test agent is an inhibitor of ClpP, wherein the test agent is a β-Lactone.
Dependencies are inferred from the claim text.